Spyre Therapeutics, Inc. — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2021-02-17

Reporting Person: Sloan Leslie (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-17	Employee Stock Option (right to buy)	$7.35	A	160000	Acquired	2031-02-16	Common Stock (160000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2021, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.